Gilead Sciences INC GILEAD SCIENCES ORD SHS
Gilead Sciences INC GILEAD SCIENC.../ US3755581036 /
0QYQ
|
24/05/2024 18:04:40
|
Diferencia
-
|
Volumen |
Bid18:30:00 |
Ask18:30:00 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
66.42USD
|
-
|
6,526
Volumen de negocios: 96,741.02 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
115.44 mil millonesUSD |
3.24% |
20.40 |
Descripción de negocio
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Consejo de gestión & Consejo de supervisión
| CEO |
| Daniel O’Day |
| Consejo de gestión |
| Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Cindy Perettie, Deborah H. Telman, Merdad Parsey |
| Consejo de supervisión |
| Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Harish Manwani, Anthony Welters, Ted W. Love, Javier J. Rodriguez |
Datos de la empresa
| Nombre: |
Gilead Sciences Inc. |
| Dirección: |
333 Lakeside Drive,Foster City, California 94404, USA |
| Teléfono: |
+1-650-574-3000 |
| Fax: |
+1-650-578-9264 |
| E-mail: |
corporate_developmen...ad.com
corporate_development@gilead.com
|
| Internet: |
www.gilead.com |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
99.89% |
| Fecha de OPI: |
22/01/1992 |
Accionistas mayoritarios
| Otros |
|
55.91% |
| BlackRock Inc. |
|
9.86% |
| Vanguard Group |
|
8.98% |
| Capital World Investors |
|
6.69% |
| CAPITAL RESEARCH GLOBAL INVESTOR |
|
4.79% |
| State Street Corporation |
|
4.78% |
| Dodge & Cox |
|
2.67% |
| GEODE CAPITAL MANAGEMENT LLC |
|
2.03% |
| Wellington Management Group |
|
1.50% |
| Otros |
|
2.80% |
